Kluwer Patent Blog

PDL Biopharma – humanized antibodies, European Patent Office (EPO Board of Appeal), 14 October 2009

Bart van Weezenbeek · Wednesday, October 14th, 2009 · Landmark European Patent Cases

This decision of the Board of Appeal covers two questions of interest: 1) May an Opposition Division include an obiter dictum in its decision? (The answer in this case is yes.) 2) To what extent is amendment in the background section of the description allowed in a divisional application?

A full summary of this case has been published on Kluwer IP Law.

Kluwer IP Law

The **2022 Future Ready Lawyer survey** showed that 79% of lawyers think that the importance of legal technology will increase for next year. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?

Learn how Kluwer IP Law can support you.

1

To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe here.

79% of the lawyers think that the importance of legal technology will increase for next year.

Drive change with Kluwer IP Law. The master resource for Intellectual Property rights and registration.





2

2022 SURVEY REPORT The Wolters Kluwer Future Ready Lawyer Leading change

This entry was posted on Wednesday, October 14th, 2009 at 2:49 am and is filed under G 1/93, OJ 1994, 541) *The 'gold standard'* of the European Patent Office's Board of Appeal is that *any amendment can only be made within the limits of what a skilled person would derive directly and unambiguously, using common general knowledge, and seen objectively and relative to the date of filing, from the whole of the documents as filed (G 3/89, OJ 1993,117; G 11/91, OJ 1993, 125).*">Amendments, antibodies, Biologics, Case Law, EPC

You can follow any responses to this entry through the Comments (RSS) feed. Both comments and pings are currently closed.